Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
The Speke, UK facility offers capabilities to manufacture human health and animal health products.
February 9, 2022
By: Tim Wright
Editor-in-Chief, Contract Pharma
TriRx Pharmaceutical Services, an international contract development and manufacturing organization (CDMO), has finalized and closed on its agreement with Elanco Animal Health to acquire the ownership and operations of its manufacturing site in Speke, UK. Elanco is one of the world’s leading animal health companies, dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. The two companies agreed a two-facility sale and long-term supply agreement in 2021, covering a facility in Shawnee, KS, and the Speke, UK site. “The Speke facility deal constitutes the second part of our acquisition and supply agreement with Elanco, following our closing on the Shawnee, Kansas facility in August 2021,” said Timothy C. Tyson, chairman CEO, TriRx. “We look forward to continuing our successful strategic partnership with this global leader. This important two-facility acquisition represents a significant step in our strategy to be a leading global CDMO in both animal health and human health. We welcome the skilled workforce at Speke to TriRx, and look forward to growing this team as we invest in the site, fulfilling the long-term supply agreement with Elanco Animal Health and bringing in new business as part of our strategic plan.” The Speke facility, initially built by Eli Lilly, offers capabilities to manufacture human health and animal health products. The sale includes the physical assets of the site and transfer of approximately 350 employees. Under the long-term supply agreement, TriRx will continue to provide Elanco with reliable delivery of its products. James Scandura, COO, TriRx, said, “The Speke facility is located close to Liverpool, UK, which is strategically important for TriRx. It is the fifth location for us and takes us to two manufacturing facilities in North America and two in Europe. It also adds API and biological capabilities to our portfolio, and further capacity capable of manufacturing both animal health and human health products.” TriRx officially took ownership of the Speke facility on February 1, 2022.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !